Cleo Diagnostics Ltd (ASX:COV)
Australia · Delayed Price · Currency is AUD 0.6300
-0.0400 (-5.97%)
At close: Feb 4, 2026
Cleo Diagnostics Company Description
Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia.
The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral.
It also focuses on developing and testing intellectual property, testing the IP, and securing patents.
Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia.
Cleo Diagnostics Ltd
| Country | Australia |
| Founded | 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| CEO | Richard Allman |
Contact Details
Address: 480 Collins Street Melbourne, VIC 3000 Australia | |
| Phone | 61 3 9614 0600 |
| Website | cleodx.com |
Stock Details
| Ticker Symbol | COV |
| Exchange | Australian Securities Exchange |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000288045 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Richard Allman Ph.D. | MD, Chief Executive Officer and Executive Director |
| Dr. Andrew N. Stephens | Chief Scientific Officer and Executive Director |
| Prof. Thomas William Jobling | Lead Medical Advisor and Independent Non-Executive Director |
| Nathan Hodgson | Head of Operations |
| Dayna Louca | Head of Corporate Development |
| Pauline M. Moffatt AAICD, B.Com., FGIA | Company Secretary |